Product Supplies was Regenerative Medical Technology’s largest product and service line in fiscal 2025, bringing in $2.02M of $5.10M (40%).
| Product and Service | FY 2020 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Product Supplies | $866.10K | $1.33M | $1.75M | $2.02M | |
| Patient Procedures | $221.26K | $319.00K | $1.37M | $1.87M | |
| Training | $279.40K | $599.43K | $809.65K | $1.13M | |
| Equipment | $163.46K | $162.37K | $177.23K | $75.84K | |
| Coins & Banknotes | — | — | — | — | |
| Total | $1.53M | $2.41M | $4.11M | $5.10M |
Regenerative Medical Technology brought in $5.10M from its four product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 24.2% from $4.11M in fiscal 2024. Product Supplies was the largest at $2.02M (39.7%), ahead of Patient Procedures at $1.87M (36.8%) and Training at $1.13M (22.1%). The remaining line, Equipment, brought in $75.84K.
Compared with fiscal 2024, Training grew fastest, up 39.0% to $1.13M. Every line above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these lines grew from $1.53M to $5.10M, a compound annual growth rate of 49.4%. Product Supplies' share of the total fell from 56.6% to 39.7%.
Regenerative Medical Technology (RMTG) reports its revenue by product and service. In fiscal 2025, Product Supplies was its largest product and service line, bringing in $2.02M (39.7% of the total), followed by Patient Procedures at $1.87M (36.8%).
Product Supplies was Regenerative Medical Technology's largest product and service line in fiscal 2025, bringing in $2.02M, or 39.7% of the $5.10M total across its four product and service lines.
Among Regenerative Medical Technology's product and service lines that make up at least 2% of revenue, Training grew fastest in fiscal 2025, up 39.0% from $809.65K to $1.13M.
Every figure comes from Regenerative Medical Technology's annual financial filings, as reported. Each line keeps the name Regenerative Medical Technology gives it, and years follow its fiscal calendar.
Regenerative Medical Technology's revenue by product and service goes back to fiscal 2020, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.